Show simple item record

Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).

dc.contributor.authorDavidson, Emma J
dc.contributor.authorFaulkner, Rebecca L
dc.contributor.authorSehr, Peter
dc.contributor.authorPawlita, Michael
dc.contributor.authorSmyth, Lucy J C
dc.contributor.authorBurt, Deborah J
dc.contributor.authorTomlinson, Anne E
dc.contributor.authorHickling, Julian K
dc.contributor.authorKitchener, Henry C
dc.contributor.authorStern, Peter L
dc.date.accessioned2009-08-25T11:18:20Z
dc.date.available2009-08-25T11:18:20Z
dc.date.issued2004-07-29
dc.identifier.citationEffect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). 2004, 22 (21-22):2722-9 Vaccineen
dc.identifier.issn0264-410X
dc.identifier.pmid15246603
dc.identifier.doi10.1016/j.vaccine.2004.01.049
dc.identifier.urihttp://hdl.handle.net/10541/78448
dc.description.abstractHeterologous prime-boost vaccination schedules employing TA-HPV, a vaccinia virus encoding HPV 16/18 E6 and E7, in combination with TA-CIN, an HPV 16 L2E6E7 fusion protein, may offer advantages over the use of either agent alone for the immunotherapy of human papillomavirus (HPV) type 16-associated vulval intraepithelial neoplasia (VIN). In the present study, 10 women with HPV 16-positive high grade VIN, previously primed with TA-HPV, received three booster immunisations with TA-CIN. All but one demonstrated HPV 16-specific proliferative T-cell and/or serological responses following vaccination. Three patients additionally showed lesion shrinkage or symptom relief, but no direct correlation between clinical and immunological responses was seen.
dc.language.isoenen
dc.subject.meshAdult
dc.subject.meshCancer Vaccines
dc.subject.meshCell Division
dc.subject.meshCervical Intraepithelial Neoplasia
dc.subject.meshDNA, Viral
dc.subject.meshEnzyme-Linked Immunosorbent Assay
dc.subject.meshFemale
dc.subject.meshGlutathione Transferase
dc.subject.meshHumans
dc.subject.meshImmunity, Cellular
dc.subject.meshImmunization Schedule
dc.subject.meshImmunization, Secondary
dc.subject.meshImmunoglobulin G
dc.subject.meshInterferon-gamma
dc.subject.meshPapillomaviridae
dc.subject.meshPhytohemagglutinins
dc.subject.meshT-Lymphocytes
dc.subject.meshVaccinia virus
dc.subject.meshVulva
dc.titleEffect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).en
dc.typeArticle
dc.contributor.departmentImmunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalVaccineen
html.description.abstractHeterologous prime-boost vaccination schedules employing TA-HPV, a vaccinia virus encoding HPV 16/18 E6 and E7, in combination with TA-CIN, an HPV 16 L2E6E7 fusion protein, may offer advantages over the use of either agent alone for the immunotherapy of human papillomavirus (HPV) type 16-associated vulval intraepithelial neoplasia (VIN). In the present study, 10 women with HPV 16-positive high grade VIN, previously primed with TA-HPV, received three booster immunisations with TA-CIN. All but one demonstrated HPV 16-specific proliferative T-cell and/or serological responses following vaccination. Three patients additionally showed lesion shrinkage or symptom relief, but no direct correlation between clinical and immunological responses was seen.


Files in this item

This item appears in the following Collection(s)

Show simple item record